Ascorbic acid 2 phosphate

modafinil solution (1 mg/mL), atomoxetine hydrochloride solution (1 mg/mL) and guanfacine hydrochloride (500 mg/mL) were dissolved in sterile dimethyl sulfoxide (DMSO). ICI-118,551-hydrochloride powder was dissolved in sterile water (10 mg/mL). All substances were purchased from Sigma-Aldrich (Steinheim, Germany). The concentrations of modafinil (11.2 µg/mL), atomoxetine (0.9 µg/mL) and guanfacine (17.7 ng/mL) were based on the maximum therapeutic plasma concentrations [11 (link),43 (link),44 (link)], and 10% DMSO was obtained from Merck, Germany. Ascorbic acid-2 phosphate (200 µM, Cayman Chemical, Ann Arbor, MI, USA), dexamethasone (0.1 µM) and ß-glycerol phosphate (10 mM, Merck, Darmstadt, Germany) were applied for osteogenic differentiation.

The ADHD medication modafinil (11.2 µg/mL), atomoxetine (0.9 µg/mL), and guanfacine (17.7 ng/mL) was ordered from Sigma-Aldrich (Steinheim, Germany) and used in max. therapeutic plasma concentration [15 (link),16 (link),17 (link)]. The medication of modafinil solution (1 mg/mL), atomoxetine hydrochloride solution (1 mg/mL) and guanfacine hydrochloride (500 mg) was purchased from Sigma-Aldrich (Steinheim, Germany) and dissolved in sterile DMSO. The osteogenic differentiation medium consisting of ascorbic acid-2-phosphate (200 µM, Cayman Chemical, Ann Arbor, MI, USA), dexamethasone (0.1 µM) and ß-glycerol phosphate (10 mM, Merck, Germany) was used. 10% DMSO was purchased from Merck, Germany.